EMA started the evaluation of Richter’s marketing authorisation application for cariprazine for the treatment of schizophrenia

Gedeon Richter Plc. (“Richter”) today announced that the European Medicines Agency (EMA) has accepted Richter’s regulatory submission for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients.